Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma News provided by Share this article Share this article PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Pr...